Entity

Time filter

Source Type

Ahmadābād, India

Shah D.V.,Intas Pharmaceuticals Ltd. | Desai C.K.,B J Medical College And Civil Hospital | Dikshit R.K.,B J Medical College And Civil Hospital | Dave D.J.,GMERS Medical College and Civil Hospital
Drugs and Therapy Perspectives | Year: 2013

Background: Cognitive and psychomotor impairment are important considerations in the management of depression. Antidepressant agents show differential effects on psychomotor performance. These are usually reversible with effective antidepressant treatment. Objective: To evaluate the effects the commonly prescribed antidepressant agents imipramine, fluoxetine and citalopram on psychomotor function in patients with depression using a battery of three simple tests. Study design: 60 adult patients with depression who had no history of taking antidepressant drugs were randomly selected from the psychiatry outpatient department of a hospital. The clinical status and psychomotor performance of patients were assessed at the beginning of treatment, and at the end of 1, 4 and 12 weeks after the initiation of treatment with imipramine, fluoxetine or citalopram. Results: Fluoxetine and citalopram showed significant improvement on psychomotor function tests relative to imipramine, and clinical condition improved to a similar extent with all the three drugs. Conclusion: In depressive patients in whom psychomotor function impairment is significantly troublesome, treatment with antidepressants with relatively non-sedating and non-impairing profiles may be preferred. © 2013 Springer International Publishing Switzerland. Source


Shah D.V.,Intas Pharmaceuticals Ltd. | Desai C.K.,B J Medical College And Civil Hospital | Dikshit R.K.,B J Medical College And Civil Hospital
Drugs and Therapy Perspectives | Year: 2014

Background: Accumulating evidence suggests that noradrenergic and serotonergic drugs are equally effective in ameliorating the depressive symptoms of major depression. Major depression is associated also with memory impairment, but the comparative effects of the antidepressant drugs on memory are not clear. Objective: To evaluate the effects the commonly prescribed antidepressant agents imipramine, fluoxetine and citalopram on memory function in patients with depression. Study design: 60 adult patients with depression who had no history of taking antidepressant drugs were randomly selected from the psychiatry outpatient department of a hospital. The clinical status and memory performance of patients were assessed at the beginning of treatment, and at the end of 1, 4 and 12 weeks after the initiation of treatment with imipramine 150 mg/day, fluoxetine 20 mg/day or citalopram 20 mg/day. Results: Although all the three drugs were equally effective with regard to the remission of depressive symptoms, fluoxetine and citalopram recipients had significantly greater improvements in memory performance than imipramine recipients. Conclusion: In depressive patients in whom memory impairment is significantly troublesome, treatment with serotonergic antidepressants may be preferred. © 2013 Springer International Publishing Switzerland. Source


Ahmad A.,Jina Pharmaceuticals Inc. | Shahabuddin S.,Jina Pharmaceuticals Inc. | Sheikh S.,Jina Pharmaceuticals Inc. | Kale P.,Lambda Therapeutic | And 3 more authors.
Clinical Pharmacology and Therapeutics | Year: 2010

Endoxifen is an active metabolite of tamoxifen, a drug used in the treatment of breast cancer. In order to be clinically effective, tamoxifen must be converted to endoxifen by cytochrome P450 2D6 (CYP2D6). A study involving single escalating oral doses was conducted in humans to evaluate the safety, tolerability, and pharmacokinetics (PK) of endoxifen. This is the first study demonstrating that single oral doses of endoxifen are safe and well tolerated and have sufficient bioavailability to reach systemically effective levels in human subjects. Furthermore, it was found that endoxifen is rapidly absorbed and systemically available and that it displays dose proportionality in peak drug concentrations in plasma (Cmax) and area under the concentration-time curve extrapolated from 0 to ∞(AUC 0-∞) over the dose range 0.5-4.0mg. © 2010 American Society for clinical Pharmacology and Therapeutics. Source


Patent
INTAS PHARMACEUTICALS Ltd | Date: 2013-10-11

The present invention relates to an improved process for the preparation of Fulvestrant (I). Also, provided is novel intermediate of Fulvestrant and a process for the preparation of the same.


Patent
INTAS PHARMACEUTICALS Ltd | Date: 2011-05-10

A process for the preparation of phenolic monoesters of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol by converting ()6-halo-4-phenylchroman-2-one to ()4-halo-2-(3-hydroxy-1-phenylpropyl)phenol. The two hydroxyl groups are protected and the protected compound is reacted with diisopropylamine to give ()[3-(2-benzyloxy-5-halophenyl)-3-phenylpropyl]diisopropylamine. The halo substituent on the benzene ring is converted to corresponding benzyl alcohol and then the protection is removed to give racemic 5-HMT. Racemic 5-HMT is converted R enantiomer and then it is esterified.

Discover hidden collaborations